Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients-Reference-Cited by-同舟云学术

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

Published:2012-05-01 Issue:1 Volume:60 Page:33-42
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Cohen Calvin J.,Molina Jean-Michel,Cahn Pedro,Clotet Bonaventura,Fourie Jan,Grinsztejn Beatriz,Wu Hao,Johnson Margaret A.,Saag Michael,Supparatpinyo Khuanchai,Crauwels Herta,Lefebvre Eric,Rimsky Laurence T.,Vanveggel Simon,Williams Peter,Boven Katia

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference24 articles.

1. . Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.;Molina;Lancet,2011

2. . Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.;Cohen;Lancet,2011

3. . Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.;Rimsky;J Acquir Immune Defic Syndr,2012

4. . Screening and baseline mutations in the TMC278 phase III trials ECHO and THRIVE: prevalence and impact on virological response abstract 41.;Vingerhoets;Antivir Ther,2011

5. . Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.;Pozniak;AIDS,2010

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial;Infectious Diseases and Therapy;2024-04-20

2. Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials;PLOS Global Public Health;2024-01-04

3. Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol;BMJ Open;2022-12

4. Accuracy of measures for antiretroviral adherence in people living with HIV;Cochrane Database of Systematic Reviews;2022-07-25

5. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine;Proceedings of the National Academy of Sciences;2022-07-19